ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1320

Categorization Of Rheumatoid Arthritis Subjects By Rheumatoid Factor and Anti-Cyclic Citrullinated Autoantibody Status Identifies Rheumatoid Arthritis Subjects With Different Characteristics

Swati Modi1, Mariely Nieves-Plaza2, Donald M. Jones3, Erich R Wilkerson4, Christine L. Amity5, Kelly A. Reckley6, Ilinca D. Metes7, Jason Lyons8, Heather Eng9, Stephen R. Wisniewski9 and Marc C. Levesque10, 1Rheumatology, University of Pittsburgh, Pittsburgh, PA, 2University of Pittsburgh, Pittsburgh, PA, 3Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 4Medicine, University of Pittsburgh, Pittsburgh, PA, 5Rheumatology & Clinical Immun, Univ of Pittsburgh, Pittsburgh, PA, 6Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 7Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Pittsburgh, Pittsburgh, PA, 8School of Public Health, Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, 9Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, 10Division of Rheumatology and Clinical Immunology, University of Pittsburgh Department of Medicine, Pittsburgh, PA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Anti-CCP antibodies and rheumatoid arthritis (RA), IL-6, Rheumatoid Factor

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects II: Predictors of Disease Course in Rheumatoid Arthritis - Treatment Approaches

Session Type: Abstract Submissions (ACR)

Background/Purpose:  Rheumatoid factor (RF) and anti-citrullinated cyclic peptide (CCP) antibodies have been used to diagnose rheumatoid arthritis (RA) patients, although there is substantial heterogeneity among RA patients regarding the presence of these biomarkers.  Previously, we found that RA patients grouped on the basis of RF and CCP status into 4 groups: RF+CCP+, RF+CCP-, RF-CCP+, RF-CCP- had different clinical characteristics including a higher percentage of female subjects and less use of biologics in the RF+CCP- group.  Our aim was to determine whether these subgroups of RA patients had features suggestive of other overlapping connective tissue diseases. 

Methods: Patients from the Rheumatoid Arthritis Comparative Effectiveness Research (RACER) registry who met the 1987 and/or 2010 ACR criteria for a diagnosis of RA were categorized based on clinical cut-offs for RF and CCP into 4 groups: RF+CCP+, RF+CCP-, RF-CCP+, RF-CCP-.  We determined the association of these four RF and CCP groups with autoantibodies and inflammatory markers measured by ELISA (IL-6) or in a clinical laboratory (ANA, anti-SSA/SSB, anti-dsDNA, C3, C4, gammaglobulin and CRP).  Categorical and continuous variables were analyzed using chi-square and Kruskal-Wallis tests, respectively. 

Results:  IL-6 levels were significantly associated with disease activity (DAS28-CRP) but only in the RF+/CCP+ and RF-/CCP- groups, while CRP levels were significantly associated with disease activity in all groups.  ANA positivity was significantly different across groups (p = 0.008) (Table 1).  The percentage of ANA positive subjects was highest in the RF+CCP+ group (71%) and lowest among the RF-/CCP- group (48%).  There were no significant differences for the remaining laboratory characteristics, although RF+/CCP- subjects were more likely to have a low C4 level and a positive anti-SSA and/or -SSB and anti-dsDNA.  

Conclusion: RF+CCP- subjects were typically ANA positive and more likely than other RF/CCP groups to be female, have low C4 levels and to have a positive anti-SSA and/or -SSB suggesting that some of these subjects may have RA and/or Sjogren’s syndrome.  The lower percentage of subjects in the CCP negative groups treated with biologic therapies may be due to lower levels of disease activity as seen in the RF-CCP- group and/or may be due to the presence of subjects with diseases poorly responsive to biologic therapies such as Sjogren’s syndrome in the RF+/CCP- group.  In summary, we believe that categorization of RA subjects by RF and CCP status may identify RA subjects with different syndromes, differential responses to therapy and different outcomes.

Table 1: Serological analysis

Serological Tests

RF-/CCP-

(n=110)

RF+/CCP-

(n=61)

RF-/CCP+

(n=33)

RF+/CCP+

(n=260)

p value

ANA  (n=379)

44/92 (48%)

34/54 (63%)

18/28 (64%)

145/205 (71%)

0.008

dsDNA  (n=32)

2/11 (18%)

2/5 (40%)

0/1 (0%)

3/15 (20%)

0.722

SSA  (n=120)

3/22 (14%)

3/19 (16%)

0/4 (0%)

10/75 (13%)

0.942

SSB  (n=113)

0/21 (0%)

2/16 (13%)

0/4 (0%)

2/72 (3%)

0.280

Low C3  (n=99)

0/30 (0%)

0/15 (0%)

0/5 (0%)

5/49 (10%)

0.963

Low C4  (n=98)

4/30 (13%)

3/15 (20%)

0/5 (0%)

5/48 (10%)

0.155

Hyper-gammaglobulinemia

(n=127)

3/32(9%)

5/18 (28%)

0/8 (0%)

21/69 (30%)

0.111


Disclosure:

S. Modi,
None;

M. Nieves-Plaza,

Genentech and Biogen IDEC Inc.,

2;

D. M. Jones,

Genentech and Biogen IDEC Inc.,

2;

E. R. Wilkerson,

Genentech and Biogen IDEC Inc.,

2;

C. L. Amity,

Genentech and Biogen IDEC Inc.,

2;

K. A. Reckley,

Genentech and Biogen IDEC Inc.,

2;

I. D. Metes,

Genentech and Biogen IDEC Inc.,

2;

J. Lyons,

Genentech and Biogen IDEC Inc.,

2;

H. Eng,

Genentech and Biogen IDEC Inc.,

2;

S. R. Wisniewski,

Genentech and Biogen IDEC Inc.,

2;

M. C. Levesque,

Genentech and Biogen IDEC Inc.,

2,

Genentech and Biogen IDEC Inc.,

5.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/categorization-of-rheumatoid-arthritis-subjects-by-rheumatoid-factor-and-anti-cyclic-citrullinated-autoantibody-status-identifies-rheumatoid-arthritis-subjects-with-different-characteristics/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology